The recommendation levels in the CSCO (Chinese Society of Clinical Oncology) guidelines serve as a bridge connecting high-level medical evidence with complex clinical decisions. They are not merely simple classifications but result from a comprehensive evaluation of evidence strength, drug accessibility, and expert consensus, directly determining which treatment plans are prioritized in clinical practice.
The CSCO guidelines primarily categorize recommendations into three levels. Level I recommendations represent the current standard of care that patients should prioritize, indicating well-established, effective, and affordable options for most patients. Level II recommendations signify treatments with high evidence levels but lower accessibility, or slightly lower evidence levels but high expert consensus. Level III recommendations indicate options with lower evidence levels that are either commonly used clinically, possess exploratory value, or are considered acceptable by experts.
In the era of evidence-based oncology treatment, the CSCO guidelines function not only as a handbook for clinicians but also as a benchmark for assessing the value of innovative drugs. Recent clinical data readouts for Zhejiang Huahai Pharmaceutical Co.,Ltd.'s HB0025, combined with chemotherapy as a first-line treatment for squamous and non-squamous non-small cell lung cancer (NSCLC), allow for an analysis based on CSCO treatment pathways. This analysis explores the drug's potential clinical positioning, market access prospects, and its pathway to differentiation in a competitive market.
Squamous and non-squamous NSCLC are the two main subtypes of lung cancer, differing in cell origin, pathological features, and affected populations. Current first-line treatment strategies are no longer based solely on morphological classification but are determined by precise molecular pathology, particularly driver gene mutation status and PD-L1 expression levels.
For patients with inoperable locally advanced or metastatic (Stage IV) NSCLC, the initial step involves genetic testing to identify potential driver gene mutations, such as EGFR, ALK, ROS1, BRAF, MET, RET, or KRAS. If a specific driver mutation is present, first-line treatment typically involves corresponding targeted therapies, such as tyrosine kinase inhibitors like osimertinib for EGFR mutations.
If no targetable driver mutations are found, the subsequent treatment choice depends on the tumor's PD-L1 expression level. For high PD-L1 expression (≥50%), single-agent immune checkpoint inhibitors like pembrolizumab or atezolizumab are often used. For low PD-L1 expression (1-49%) or negative expression (<1%), the standard approach is an immune checkpoint inhibitor combined with platinum-based doublet chemotherapy. This is the most common regimen, applicable to both squamous and non-squamous carcinoma, though the specific chemotherapy drugs used may differ.
HB0025 is an innovative anti-PD-L1/VEGF bispecific fusion protein independently developed by Huahai's subsidiary, Huaota Biopharma. Phase II clinical data for HB0025 plus chemotherapy in first-line treatment of advanced lung squamous cell carcinoma and lung adenocarcinoma, presented at the 2025 ESMO conference, showed an objective response rate (ORR) of 83.3% in the squamous NSCLC cohort. The ORR reached 100% in the PD-L1 high expression subgroup, with a disease control rate (DCR) of 95.8%. In the non-squamous cohort, the ORR was 56.4%, with a DCR of 94.9%. Regarding safety, the incidence of Grade 3 or higher immune-related adverse events (irAEs) was low, indicating good tolerability.
Based on current data, HB0025 combined with chemotherapy shows promising signals for ORR and DCR. These figures appear favorable in non-head-to-head comparisons with other immune checkpoint inhibitors combined with chemotherapy. For instance, the RATIONALE-304 study reported an ORR of approximately 57.8% for tislelizumab plus chemotherapy in first-line advanced non-squamous NSCLC. The GEMSTONE-302 study showed an ORR of about 61.4% for sugemalimab plus chemotherapy in first-line treatment of advanced squamous and non-squamous NSCLC.
However, meta-analysis results indicate no significant correlation between overall survival (OS) benefit and ORR or progression-free survival (PFS). Short-term efficacy benefits do not necessarily translate into significant long-term OS advantages. Ultimately, median overall survival (mOS) remains the gold standard for determining a drug's value. This means that while HB0025 combination therapy demonstrated impressive ORR data in the Phase II study, even achieving 100% in some subgroups, these short-term efficacy indicators are insufficient to conclusively define its clinical value.
From a competitive perspective, the market is already highly saturated. Domestically, several PD-1/PD-L1 inhibitors are approved and recommended by CSCO guidelines for first-line treatment of driver gene-negative NSCLC, including pembrolizumab, sintilimab, tislelizumab, camrelizumab, and sugemalimab. Most of these are already included in the National Reimbursement Drug List, creating significant market barriers.
Beyond the intense competition among numerous reimbursed drugs, PD-1 biosimilars, represented by Bio-Thera Solutions' BAT3306, are nearing the final stages of approval. In the near future, the market will face not only competition among similar products but also comprehensive pressure from lower-priced biosimilars, further intensifying competition. Although HB0025, as a PD-L1/VEGF bispecific fusion protein, has the potential synergy of targeting two mechanisms with one agent, breaking through in such a crowded field remains challenging.
Looking at comparable products, Akeso's ivonescimab (a PD-1/VEGF bispecific antibody) has been approved in China, but its primary indication is combined with chemotherapy for EGFR-mutant NSCLC after resistance to targeted therapy (CSCO Level I recommendation). For driver gene-negative NSCLC, ivonescimab monotherapy is only recommended for treating the PD-L1 low-expression population (CSCO Level II recommendation).
In terms of market size, NSCLC, being the malignancy with the highest incidence and mortality rates in China, represents a substantial first-line treatment market. According to data from the National Cancer Center, there are approximately 800,000 new lung cancer cases annually in China, with NSCLC accounting for about 85%. Roughly 75% of these are diagnosed at an advanced stage, equating to approximately 500,000 cases.
Among these, about 50% are driver gene-negative and suitable for immunotherapy combined with chemotherapy. Estimating an annual treatment cost of 60,000 to 100,000 RMB, the potential market size for first-line therapy ranges from 15 to 25 billion RMB. Even amidst fierce competition, if HB0025 can capture just 3% to 5% of this market share, it could achieve annual sales of 500 million to 1.25 billion RMB, demonstrating potential to become a core product for the company.
Comments